Large Uremic Toxins: an Unsolved Problem in End-stage Kidney Disease

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2018 Oct 4

PMID 30281131

Citations 22

Authors

Martin J Wolley

Colin A Hutchison

Affiliations

Soon will be listed here.

Abstract

Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis are subject to a high burden of inflammation and cardiovascular disease, driven at least in part by retention of uremic solutes. Existing dialysis technologies using high-flux membranes offer limited clearance of solutes >15 kDa. New approaches to improve the removal of large uremic toxins include the novel medium cut-off dialysis membranes with pores larger than those in high-flux membranes. These new membranes provide the potential to improve the clearance of large middle molecules up to 50 kDa. In this review, we discuss 18 uremic toxins with molecular weights between 15 and 60 kDa that are retained in ESKD, for which there is evidence of a link to inflammation and/or cardiovascular disease. These include inflammatory proteins, cytokines, adipokines and other signaling proteins. Improved clearance of this group of difficult to remove molecules has the potential to lead to improved outcomes in dialysis patients by reducing the burden of cardiovascular disease, which now needs to be assessed in robust clinical trials.

Citing Articles

Benefits and Pitfalls of Uraemic Toxin Measurement in Peritoneal Dialysis.

Malaweera A, Huang L, McMahon L J Clin Med. 2025; 14(4).

PMID: 40004925 PMC: 11857055. DOI: 10.3390/jcm14041395.

The Efficacy of Zinc Gluconate Supplementation in the Improvement of Malnutrition Indices and Skin Abnormalities in Hemodialysis Patients: A Randomized Clinical Trial.

Tavassoli M, Shahidi S, Askari G, Tavakoli N, Clark C, Rouhani M Int J Prev Med. 2025; 15:63.

PMID: 39742128 PMC: 11687676. DOI: 10.4103/ijpvm.ijpvm_206_23.

Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment.

Johnson F, Wu S, Schmith G, Williams H, Rutecki J, Halabi A PLoS One. 2024; 19(12):e0314030.

PMID: 39636942 PMC: 11620666. DOI: 10.1371/journal.pone.0314030.

Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.

Frak W, Dabek B, Balcerczyk-Lis M, Motor J, Radzioch E, Mlynarska E Antioxidants (Basel). 2024; 13(6).

PMID: 38929126 PMC: 11200916. DOI: 10.3390/antiox13060687.

The Prognostic Role of Serum β-Trace Protein Levels among Patients on Maintenance Hemodialysis.

Huang P, Hsu B, Wang C, Tsai J Diagnostics (Basel). 2024; 14(10).

PMID: 38786272 PMC: 11119092. DOI: 10.3390/diagnostics14100974.

References

Henle T, Deppisch R, Beck W, Hergesell O, Hansch G, Ritz E . Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant. 1999; 14(8):1968-75. DOI: 10.1093/ndt/14.8.1968. View

Weber C, Duchateau-Nguyen G, Solier C, Schell-Steven A, Hermosilla R, Nogoceke E . Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. Clin Kidney J. 2014; 7(2):167-173. PMC: 3968563. DOI: 10.1093/ckj/sfu017. View

Tong M, Carrero J, Qureshi A, Anderstam B, Heimburger O, Barany P . Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007; 2(5):889-97. DOI: 10.2215/CJN.00870207. View

Carrero J, Kyriazis J, Sonmez A, Tzanakis I, Qureshi A, Stenvinkel P . Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2011; 7(2):207-15. PMC: 3280028. DOI: 10.2215/CJN.06840711. View

Formanowicz D, Wanic-Kossowska M, Pawliczak E, Radom M, Formanowicz P . Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney disease--systems and clinical approach. Sci Rep. 2015; 5:18332. PMC: 4680867. DOI: 10.1038/srep18332. View

Yamagishi S, Edelstein D, Du X, Kaneda Y, Guzman M, Brownlee M . Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276(27):25096-100. DOI: 10.1074/jbc.M007383200. View

Bozic M, Betriu A, Bermudez-Lopez M, Ortiz A, Fernandez E, Valdivielso J . Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. Clin J Am Soc Nephrol. 2018; 13(4):577-584. PMC: 5969461. DOI: 10.2215/CJN.07980717. View

Pawlak K, Rozkiewicz D, Mysliwiec M, Pawlak D . YKL-40 in hemodialyzed patients with and without cardiovascular complications - the enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine. 2013; 62(1):75-80. DOI: 10.1016/j.cyto.2013.02.014. View

Orenes-Pinero E, Manzano-Fernandez S, Lopez-Cuenca A, Marin F, Valdes M, Januzzi J . β-Trace protein: from GFR marker to cardiovascular risk predictor. Clin J Am Soc Nephrol. 2013; 8(5):873-81. DOI: 10.2215/CJN.08870812. View

10.

Hutchison C, Cockwell P, Reid S, Chandler K, Mead G, Harrison J . Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18(3):886-95. DOI: 10.1681/ASN.2006080821. View

11.

Swerdlow D, Holmes M, Kuchenbaecker K, Engmann J, Shah T, Sofat R . The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012; 379(9822):1214-24. PMC: 3316968. DOI: 10.1016/S0140-6736(12)60110-X. View

12.

Ayerden Ebinc F, Ebinc H, Derici U, Aral A, Aybay C, Tacoy G . The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol. 2009; 22(2):216-23. View

13.

Klouche M, Peri G, Knabbe C, Eckstein H, Schmid F, Schmitz G . Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004; 175(2):221-8. DOI: 10.1016/j.atherosclerosis.2004.03.020. View

14.

Ali F, Falkner B, Gidding S, Price H, Keith S, Langman C . Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. J Pediatr. 2014; 165(4):738-43.e1. PMC: 4177448. DOI: 10.1016/j.jpeds.2014.06.027. View

15.

Shafi T, Parekh R, Jaar B, Plantinga L, Oberai P, Eckfeldt J . Serum β-trace protein and risk of mortality in incident hemodialysis patients. Clin J Am Soc Nephrol. 2012; 7(9):1435-45. PMC: 3430954. DOI: 10.2215/CJN.02240312. View

16.

Schultz J, Witt S, Nieman M, Reiser P, Engle S, Zhou M . Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999; 104(6):709-19. PMC: 408439. DOI: 10.1172/JCI7315. View

17.

Ok E, Asci G, Toz H, Sevinc Ok E, Kircelli F, Yilmaz M . Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2012; 28(1):192-202. DOI: 10.1093/ndt/gfs407. View

18.

Kahn M, Robbins M, Kim M, Fuster V . Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol. 2013; 10(5):261-73. DOI: 10.1038/nrcardio.2013.15. View

19.

Galea J, Armstrong J, Gadsdon P, HOLDEN H, Francis S, Holt C . Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996; 16(8):1000-6. DOI: 10.1161/01.atv.16.8.1000. View

20.

Wallace A, McMahon A, Packard C, Kelly A, Shepherd J, Gaw A . Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104(25):3052-6. DOI: 10.1161/hc5001.101061. View